Positive and Negative Syndrome Scale (PANSS)

The PANSS (30 items, 1–7 scale, three subscales) provides more granular assessment than the BPRS (18 items, 1–7 scale, 5 factors). The PANSS explicitly separates positive from negative symptoms and includes more detailed general psychopathology items. The BPRS is shorter and used in rapid screening or longitudinal follow-up, while PANSS is preferred in research trials and baseline comprehensive assessment. Both are clinician-rated; neither is suitable for self-report.

First-generation (typical) and second-generation (atypical) antipsychotics typically reduce Positive Scale scores by 30–50% over 6–12 weeks, with earlier onset than Negative scale improvement. General Psychopathology (anxiety, agitation, depression) improves within days to weeks. Negative symptoms often show slower improvement or may remain stable; some atypical antipsychotics (aripiprazole, amisulpride) show slightly better negative symptom efficacy. Failure to improve Positive scores within 4 weeks suggests treatment resistance and warrants dose optimization or medication switch.

The PANSS can be used descriptively in other psychotic disorders, but it was developed and validated in schizophrenia and is most reliable in that population. For bipolar mania, the Young Mania Rating Scale (YMRS, 11 items) is more specific and sensitive to mood elevation. For bipolar depression with psychosis, use the Montgomery-Asberg Depression Rating Scale (MADRS) supplemented with psychotic item assessment. The PANSS can be administered but comparisons to schizophrenia norms are not appropriate.

A 20% reduction from baseline total PANSS is considered treatment response in trials; 50% reduction is remission. For subscales: a ≥5–7 point reduction on Positive or Negative scale represents clinically meaningful change. In the Positive scale (range 7–49), a drop from 28 to 22 (6-point reduction) is clinically significant. PANSS is sensitive to changes over weeks to months but requires baseline and follow-up assessment 4+ weeks apart for meaningful comparison.

Yes, for first-episode psychosis (FEP) in research or specialized early intervention programs, baseline PANSS is standard. In routine clinical practice, clinician judgment determines frequency; typical intervals are baseline, 2–4 weeks, 8–12 weeks during acute treatment, then monthly to quarterly if stable. For maintenance therapy, 6–12 month intervals may suffice. Repeated administration is essential if changing medications or if symptoms are not improving as expected (suggests treatment resistance).

Elevated Negative subscale (items 8–14) in schizophrenia + depression requires careful interpretation. Items like 'blunted affect' and 'emotional withdrawal' can reflect primary negative symptoms or secondary depression. Use the General Psychopathology scale (especially depression item 16, guilt item 15, anxiety item 12) to gauge depressive contribution. If depression items are also elevated, the high Negative score may be partly mood-driven; antidepressant augmentation plus antipsychotic may be indicated. Primary negative symptoms persist despite depression treatment, warranting alternative approaches.